Health Care [ 10/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
The company focuses on the discovery of G-protein coupled receptors and enzymes.
Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia.
The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder.
It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases.
The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 19, 25 | -2.00 Decreased by -4.90 K% | - |
| Nov 11, 24 | 10.17 Increased by +3.89 K% | - |
| Jun 6, 24 | -4.06 Decreased by -194.01% | -0.03 Decreased by -13.03 K% |
| Nov 13, 23 | -4.60 Decreased by -5.01 K% | -0.03 Decreased by -14.79 K% |
| Aug 10, 23 | -0.04 Increased by +96.64% | -0.04 |
| May 11, 23 | -0.27 Increased by +70.62% | -0.05 Decreased by -420.16% |
| Mar 30, 23 | -1.38 Decreased by -69.30% | -0.05 Decreased by -2.57 K% |
| Nov 11, 22 | -0.09 Increased by +87.55% | -0.09 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 1.51 K Decreased by -99.36% | -1.47 M Increased by +52.29% | Decreased by -97.67 K% Decreased by -7.33 K% |
| Dec 31, 24 | 1.51 K Decreased by -99.02% | -1.21 M Increased by +57.79% | Decreased by -79.96 K% Decreased by -4.19 K% |
| Sep 30, 24 | 53.84 K Decreased by -83.57% | -1.53 M Increased by +41.54% | Decreased by -2.84 K% Decreased by -255.88% |
| Jun 30, 24 | 115.28 K Decreased by -81.73% | 12.88 M Increased by +581.42% | Increased by +11.17 K% Increased by +2.73 K% |
| Mar 31, 24 | 234.91 K Decreased by -53.10% | -3.09 M Decreased by -28.25% | Decreased by -1.31 K% Decreased by -173.46% |
| Dec 31, 23 | 153.45 K Decreased by -74.10% | -2.86 M Increased by +21.76% | Decreased by -1.86 K% Decreased by -202.04% |
| Sep 30, 23 | 327.73 K Decreased by -19.95% | -2.62 M Increased by +36.29% | Decreased by -798.54% Increased by +20.41% |
| Jun 30, 23 | 630.88 K Increased by +244.08% | -2.68 M Increased by +62.95% | Decreased by -424.04% Increased by +89.23% |